Introduction
Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma (NHL). The world prevalence is approximately 650,000 cases, of which 300,000 are low grade and 350,000 are aggressive. The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide thru this field and bring structure and knowledge enable our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.
Research and analysis highlights
At the American Society of Clinical Oncology 2005 meeting new investigations showed that freedom from treatment failure was significantly better for patients with Hodgkin’s disease undergoing transplantation compared to non-transplant salvage, regardless of whether they relapse early or late following primary chemotherapy. Rituximab has been heavily investigated in a variety of treatment regimes. Published trial data show an increase in response rates when rituximab is combined with current chemotherapy regimens in both the first- and second- line settings. In addition, rituximab show significant off-label usage. Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.
Scope of this report
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current treatment strategies.
- Company profiles and their anticancer pipeline of most companies in the field
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in lymphoma R&D, and the results of clinical trials to date.
- Gain insight into the current challenges and commercial opportunities associated with lymphoma therapy
Some of the drugs included in this analysis:
Aldesleukin , Apolizumab, Arsenic trioxide, Bevacizumab, BiovaxID , Bortezomib , CMC-544 , Enzastaurin , Epratuzumab, FavId , Flavopiridol, Genasense , IDEC-114 , Marqibo, MyVax, Nelarabine , Pixantrone , SGN-30, SGN-40 , Temsirolimus , Zanolimumab.
Some of the companies included in this analysis
Accentia BioPharmaceuticals, Biogen , Cell Therapeutics , Cephalon , Chiron (now Novartis) Corporation , Eli Lilly , Favrille , Genentech , Genitope , Genmab , Genta , GlaxoSmithKline, Immunomedics , Inex Pharmaceuticals , Millennium Pharmaceuticals, Protein Design Labs , Roche, Sanofi-Aventis, Seattle Genetics , Wyeth.
1 Executive Summary
2 Cancer Highlights
3 Methodology
4 Table of Contents
4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables
5 Introduction
5.1 Disease Definition
5.2 Etiology & Pathophysiology
5.3 Epidemiology
6 Current Treatment Strategies
6.1 Hodgkin’s Disease
6.1.1 Radiation Therapy
6.1.2 Chemotherapy
6.1.3 Transplantation
6.1.4 Treatment Option Overview
6.2 Non-Hodgkin’s Lymphoma
6.2.1 Radiation Therapy
6.2.2 Chemotherapy
6.2.3 Immunotherapy
6.2.4 Bone Marrow and Peripheral Blood Transplants
6.2.5 Watch and Wait
6.2.6 Treatment Option Overview
6.3 Prognosis
6.3.1 Hodgkin’s Disease
6.3.2 Non-Hodgkin
7 Progress in Current Treatment Strategies
7.1 HODGKIN
7.2 NON-HODGKIN
7.3 Rituxan
7.4 Bexxar
7.5 Zevalin
8 Key Therapeutic Strategies
8.1 Antibodies & Immunostimulation
8.2 Small molecules: Apoptosis inducers & Kinase inhibitors
9 Competitive Landscape in Drug Development: The Late Stage Pipeline
10 Current Drug Development: The Early Stage Pipeline
11 Disclaimer
11.1 Liability
11.2 Completeness
12 Appendix 1: Selected Companies – Anticancer Pipelines
12.1 Accentia BioPharmaceuticals
12.2 Biogen Idec
12.3 Cell Therapeutics
12.4 Cephalon
12.5 Chiron Corporation (Now Novartis)
12.6 Eli Lilly
12.7 Favrille
12.8 Genentech
12.9 Genitope Corporation
12.10 Genmab
12.11 Genta
12.12 GlaxoSmithKline
12.13 Immunomedics
12.14 Inex Pharmaceuticals
12.15 Millennium Pharmaceuticals
12.16 Protein Design Labs
12.17 Roche
12.18 Sanofi-Aventis
12.19 Seattle Genetics
12.20 Wyeth
Company & Drug Index
4.1 List of Boxes
Box 1 Possible Complications of Treatment
Box 2 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 3 Subclassification of Stage
Box 4 Updated REAL/WHO Classification for B-Cell Neoplasms
Box 5 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms
Box 6 Staging subclassification system
Box 7 Study details
4.2 List of Figures
Figure 1: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.
4.3 List of Tables
Table 1 Drugs used in the treatment of lymphoma.
Table 2 Summary of Strategies Enhancing Antibody Function
Table 3 Cancer immunotherapy strategies.
Table 4 Protein Kinase Targets in Clinical Trials for Lymphoma
Table 5 Recent published studies Aldesleukin
Table 6 Recent published studies Arsenic trioxide
Table 7 Recent published studies BiovaxID
Table 8 Recent published studies Bortezomib
Table 9 Recent published studies epratuzumab
Table 10 Recent published studies FavId
Table 11 Recent published studies MyVax
Table 12 Recent published studies Nelarabine
Table 13 Recent published studies Genasense
Table 14 Recent published studies Pixantrone
Table 15 Recent published studies temsirolimus
Table 16 Recent published studies Zanolimumab
Table 17 Recent published studies Flavopiridol
Table 18 Recent published studies bevacizumab
Table 19 Recent published studies CMC-544
Table 20 Recent published studies galiximab
Table 21 Recent published studies LY317615
Table 22 Recent published studies SGN-40
Table 23 Recent published studies Apolizumab
Table 24 Recent published studies SGN-30
Table 25 Accentia BioPharmaceuticals’ Anticancer Pipeline
Table 26 Biogen-Idec’s Anticancer Pipeline
Table 27 Cell Therapeutics’ Anticancer Pipeline
Table 28 Cephalon’s Anticancer Pipeline
Table 29 Chiron´s Anticancer Pipeline
Table 30 Eli Lilly’s Anticancer Pipeline
Table 31 Favrille anticancer pipeline
Table 32 Genentech’s Anticancer Pipeline
Table 33Genitope’s Anticancer Pipeline
Table 34 Genmab’s Anticancer Pipeline
Table 35 Genta’s Anticancer Pipeline
Table 36 GlaxoSmithKline’s Anticancer Pipeline
Table 37 Immunomedics’ Anticancer Pipeline
Table 38 Inex Pharmaceuticals’ Anticancer Pipeline
Table 39 Millennium Pharmaceuticals’ Anticancer Pipeline
Table 40 Protein Design Labs’ Anticancer Pipeline
Table 41 Roche’s Anticancer Pipeline
Table 42 Sanofi-Aventis anticancer pipeline
Table 43 Seattle Genetics’ Anticancer Pipeline
Table 44 Wyeth’s Anticancer Pipeline
- Accentia BioPharmaceuticals
- Biogen
- Cell Therapeutics
- Cephalon
- Chiron (now Novartis) Corporation
- Eli Lilly
- Favrille
- Genentech
- Genitope
- Genmab
- Genta
- GlaxoSmithKline
- Immunomedics
- Inex Pharmaceuticals
- Millennium Pharmaceuticals
- Protein Design Labs
- Roche
- Sanofi-Aventis
- Seattle Genetics
- Wyeth
Other selected research from the 'Cancer Highlights' category:
Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight
Apoptosis: Promise or deception?
Other selected research from the 'Triple Analysis' category:
Triple Analysis: Colorectal Cancer, Lung Cancer and Antibodies
Triple Analysis: Leukemia, Pancreatic Cancer and Angiogenesis
Other selected research from the 'Oncology' category:
Triple Analysis: Lung Cancer, Prostate Cancer and Peptides
Stakeholder Opinions: Cancer Cachexia - Higher profile needed to unlock market potential of neglected syndrome
Other selected research from the 'Targeted' category:
Monoclonal Antibodies Report: 2008 Update
Pipeline Insight: Therapeutic Cancer Vaccines - A turbulent path from bench to bedside